TY - JOUR
T1 - Precision medicine for NSCLC in the era of immunotherapy: New biomarkers to select the most suitable treatment or the most suitable patient
AU - Rossi, Giovanni
AU - Russo, Alessandro
AU - Tagliamento, Marco
AU - Tuzi, Alessandro
AU - Nigro, Olga
AU - Vallome, Giacomo
AU - Sini, Claudio
AU - Grassi, Massimiliano
AU - Dal Bello, Maria Giovanna
AU - Coco, Simona
AU - Longo, Luca
AU - Zullo, Lodovica
AU - Tanda, Enrica Teresa
AU - Dellepiane, Chiara
AU - Pronzato, Paolo
AU - Genova, Carlo
PY - 2020/5
Y1 - 2020/5
N2 - In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatly influenced the outcomes of a large proportion of NSCLC patients. While nivolumab activity was initially assessed irrespective of predictive biomarkers, subsequent pivotal studies involving other PD-1/PD-L1 inhibitors in pre-treated advanced NSCLC (atezolizumab within the OAK study and pembrolizumab in the Keynote 010 study) reported the first correlations between clinical outcomes and PD-L1 expression. However, PD-L1 could not be sufficient on its own to select patients who may benefit from immunotherapy. Many studies have tried to discover more precise markers that are derived from tumor tissue or from peripheral blood. This review aims to analyze any characteristics of the immunogram that could be used as a predictive biomarker for response to ICIs. Furthermore, we describe the most important genetic alteration that might predict the activity of immunotherapy.
AB - In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatly influenced the outcomes of a large proportion of NSCLC patients. While nivolumab activity was initially assessed irrespective of predictive biomarkers, subsequent pivotal studies involving other PD-1/PD-L1 inhibitors in pre-treated advanced NSCLC (atezolizumab within the OAK study and pembrolizumab in the Keynote 010 study) reported the first correlations between clinical outcomes and PD-L1 expression. However, PD-L1 could not be sufficient on its own to select patients who may benefit from immunotherapy. Many studies have tried to discover more precise markers that are derived from tumor tissue or from peripheral blood. This review aims to analyze any characteristics of the immunogram that could be used as a predictive biomarker for response to ICIs. Furthermore, we describe the most important genetic alteration that might predict the activity of immunotherapy.
KW - Biomarker
KW - Immune checkpoint inhibitor
KW - NSCLC
KW - PD-L1
KW - POLE
KW - PTEN inactivation
KW - STK11
KW - T-Cell clonality
KW - Tumor mutational burden
UR - http://www.scopus.com/inward/record.url?scp=85084232713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084232713&partnerID=8YFLogxK
U2 - 10.3390/cancers12051125
DO - 10.3390/cancers12051125
M3 - Review article
AN - SCOPUS:85084232713
VL - 12
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 5
M1 - 1125
ER -